CIMMYT's eastern Africa product pipeline 1B (EA-PP1B) focuses on developing high-yielding, early maturing maize varieties with white grain, drought tolerance, NUE, and resistance to GLS, TLB, and ear rots, that are suitable for food use in tropical, rainfed, dry, mid-altitude areas in eastern Africa and similar agroecologies. |
|
General Information |
|
Adaptation/Agroecological zone |
1000 - 1600 masl |
|
Type of product |
Three-way cross hybrid |
|
Year first announced |
2017 |
|
|
|
|
Grain Characteristics |
|
Grain color |
White |
|
|
|
Grain texture |
Semi dent |
Grain Yield |
|
|
|
Grain yield under optimum conditions |
9.45 t/ha |
|
Biotic Stress Performance |
Grain yield under high density |
8.1 t/ha |
|
Turcicum leaf blight (TLB) (1-9) |
3.7 |
Grain yield under random stress |
4.9 t/ha |
|
Grey leaf spot (GLS) (1-9) |
2.7 |
Grain yield under low N stress |
3.56 t/ha |
|
Common rust (1-9) |
2.9 |
Grain yield under striga conditions |
3.6 t/ha |
|
Maize lethal necrosis (MLN) under art. inoc. (1-9) |
5.4 |
|
|
|
Ear rots |
4.5% |
Agronomic Characteristics |
|
Diseases were originally scored on a 1-5 scale but have been converted here to a 1-9 scale, where 1 = Highly resistant; 5 = Tolerant; 9 = Highly susceptible. |
Maturity |
107 DAP |
|
Plant height |
217.6 cm |
|
|
|
Ear height |
96.7 cm |
|
Seed Production Characteristics |
Bad husk cover |
14.6% |
|
Nicking |
-2 Days |
Root lodging |
2.3% |
|
|
|
Stalk lodging |
11.3% |
|
Comments |
Anther-silking interval |
1.0 Days |
|
Product information is based on data from various trials conducted by CIMMYT in eastern Africa in 2016.
Abbreviations:
art. inoc. = artificial inoculation
DAP = days after planting
GLS = Grey Leaf Spot
HD = High Density (80,000 plants per ha)
Low N = Managed Low Nitrogen
masl = meters above sea level
MSV = maize streak virus
NUE = Nitrogen Use Efficient
TLB = Turcicum Leaf Blight |
Ear aspect (1-5) |
2.8 |
|
Plant aspect (1-5) |
2.4 |
|
Plant and ear aspects are scored on 1-5 scale, where 1 = desirable and 5 = undesirable characteristics |
|
|
|
|
|
Further Links |
|
Full Announcement |
|
Trial Data Summary |
|
Regional Trial Site Information |
|
|
|
|